• Perospirone: Neuropsychiatric and Vascular Evidence

  2026-10-07

  Perospirone is best understood as a receptor-active atypical antipsychotic with an emerging, experimentally defined vascular ion-channel signal. This overview separates established pharmacological context from the findings of a 2025 rabbit-cell study and explains why the Kv1.5 result is hypothesis-generating rather than proof of clinical cardiovascular effects.

• Bay 11-7085 and NF-κB Signaling: Evidence Overview

  2026-10-06

  Bay 11-7085 is a pharmacological research probe used to interrogate NF-κB-related inflammatory signaling, but the strength of evidence depends heavily on model, endpoint, and source provenance. This overview compares supplier-level claims with findings from a 2024 subarachnoid hemorrhage study and explains what can—and cannot—be inferred across disease contexts.

• ABT-888 (Veliparib): Reading PARP Evidence

  2026-10-06

  ABT-888, also known as Veliparib, is a selective PARP1/2 inhibitor used to study DNA repair inhibition and treatment resistance. This evidence-focused guide connects its preclinical sensitizer profile with new biomarker insights from high-grade serous ovarian cancer research.

• Nystatin and Polyene Synergy in Candida Research

  2026-10-05

  This overview examines Nystatin (Fungicidin) as a polyene antifungal, focusing on ergosterol-targeted activity, recent moxidectin combination research, preclinical findings in oral candidiasis, evidence strength, and boundaries around clinical and cross-species interpretation.

• Tioconazole Research Context and Evidence Boundaries

  2026-10-05

  This evidence-focused overview explains Tioconazole’s azole antifungal context and distinguishes it from a 2025 AML study on energy deficiency, ATG4B, PRMT1, and MRE11. It compares mechanistic evidence, identifies conceptual applications in antifungal drug development, and clarifies why the leukemia findings do not establish a Tioconazole effect on DNA repair or the ATG4B pathway.

• PPP2R2A Loss Sensitizes HGSOC to CHK1 Inhibition

  2026-10-04

  A 2024 Theranostics study identifies low PPP2R2A expression as a potential biomarker of sensitivity to CHK1 inhibition in high-grade serous ovarian cancer. The findings connect PP2A B55α deficiency with increased replication stress and suggest a strategy for studying tumors that remain resistant to PARP inhibitors.

• AAPH and Lipid Peroxidation: Five Evidence Questions

  2026-10-03

  A source-grounded overview of AAPH as a reactive oxygen species generator, what oxidative-stress readouts can and cannot show, and how its scope differs from mechanistic ferroptosis research.

• Silymarin Workflows for Translational Bench Research

  2026-10-01

  Silymarin is a chemically diverse milk thistle extract suited to oxidative-stress, cancer, metabolic, and antiviral assay development when formulation and composition are controlled. This practical guide connects silymarin chemistry with executable workflows, orthogonal readouts, and troubleshooting strategies for more interpretable results.

• ATG4B Nuclear Translocation and AML DNA Repair

  2026-10-01

  The 2025 Advanced Science study identifies an energy-sensitive ATG4B–PRMT1–MRE11 axis that connects metabolic stress with defective DNA repair and acute myeloid leukemia progression. By combining mechanistic experiments with AML cell, mouse, and patient-derived xenograft models, the study shows that ATG4B inhibition can restore DNA damage responses and reduce malignant evolution, while also defining important limits for translation.

• Morin, AMPD2, and Podocyte Energy Metabolism

  2026-09-30

  A 2025 study identifies adenosine 5′-monophosphate deaminase 2 (AMPD2) within the purine nucleotide cycle as a mechanistic link between fructose exposure, podocyte mitochondrial dysfunction, and glomerular injury. Using complementary rat, podocyte, molecular-docking, and siRNA experiments, the authors show that Morin reduces AMPD activity and improves energy-metabolism abnormalities, while also defining important limits for translation beyond this model.

• Nystatin (Fungicidin): Mechanism and Research Use

  2026-09-30

  Nystatin (Fungicidin) is a polyene antifungal antibiotic that targets ergosterol-rich fungal membranes. Product-reported benchmarks support research on Candida species, adhesion, and liposomal Aspergillus models, while formulation and assay limitations require careful interpretation.

• Palonosetron hydrochloride: Assay Workflows

  2026-09-29

  Build more informative 5-HT3 receptor assays by pairing nanomolar receptor pharmacology with transporter-focused exposure ranges. This workflow shows how Palonosetron hydrochloride supports cancer research, chemotherapy-induced nausea and vomiting prevention, radiotherapy-induced nausea and vomiting prevention, and renal interaction studies.

• CCK8 in Osteoblast Research: From Signal to Biology

  2026-09-29

  Discover how Cell Counting Kit-8 (CCK-8) can strengthen osteoblast proliferation and viability studies without confusing metabolic signal with differentiation. This guide connects WST-8 assay design to the Prmt1–Ddx17–Sh2b1 mechanism reported in osteoporosis research.

• Protein A/G Magnetic Co-IP/IP Kit Workflow

  2026-09-28

  Build reproducible protein complex isolation workflows around magnetic Fc capture, from lysate preparation through SDS-PAGE or mass spectrometry. The approach translates the RNF8–DAPK1 interaction strategy from ischemic-stroke research into practical co-immunoprecipitation, antibody-purification, and troubleshooting decisions.

• Of Chloroquine and COVID-19: Evidence Before Extrapolation

  2026-09-28

  Touret and de Lamballerie’s 2020 commentary places early interest in chloroquine for COVID-19 against a mixed record of antiviral results across cell, animal, and human studies. Its central contribution is a caution about translating in-vitro activity into clinical benefit: prior human trials had not established chloroquine as an effective treatment for acute viral infections, and toxicity and disease-specific effects matter.

7972 records 1/532 page Next 12345 下5页 Last page